PAR 3.77% 25.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-3614

  1. 9,800 Posts.
    lightbulb Created with Sketch. 1241
    Its a summary 281 other studies by academics with diverse background. Not sure how you could classify it as predatory. Would have disclosed their conflict of interest if it was really paid for research




 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.